Skip to main content
. 2020 May 25;40(7):313–315. doi: 10.1002/cac2.12035

FIGURE 1.

FIGURE 1

Illustration of the oncogenic role of lncRNA AGPG in driving p53‐deficient ESCC development. Loss of p53 promotes AGPG expression, which in turn forms a complex with PFKFB3 to induce glycolysis and cell cycle progression. This AGPG‐dependent oncogenic alteration contributes to the ESCC development and could be used as a therapeutic target for ESCC treatment